Zentalis Lawsuit Submission Form | Securities Class Action Lawyers

Return to Home

Zentalis Pharmaceuticals, Inc.

ZNTL

Find Out if You Qualify for a Financial Reward by filling out the form below.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Owned

Purchase Date

Estimated Loss

Securities Fraud News does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

Zentalis announced on June 18, 2024, that “the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).”

Following this news, Zentalis’s stock price fell over 50% on June 18, 2024.

Zentalis Pharmaceuticals, Inc.

ZNTL

Zentalis Pharmaceuticals, Inc. Form

Find More Cases